Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Global DNA Sequencing in Drug Discovery Market Report 2026 | Capitalize on 12.5% CAGR as Illumina, Thermo Fisher, QIAGEN, and Oxford Nanopore Accelerate AI-Driven Precision R&D

globenewswire.com
ILMN Illumina is mentioned as a key player in the global DNA sequencing market, which is experiencing rapid growth driven by advancements in precision medicine and AI-driven R&D. The article highlights the overall market trends and growth factors without specific sentiment towards Illumina itself. TMO Thermo Fisher Scientific is listed as a significant company in the DNA sequencing market. The article focuses on the overall market growth and technological advancements, not providing specific sentiment or performance details for Thermo Fisher. QGEN QIAGEN is identified as a company within the DNA sequencing market. The article discusses the market's expansion and key drivers like AI and personalized medicine, but does not offer specific sentiment or news related to QIAGEN. ONON Oxford Nanopore Technologies is mentioned as a key participant in the DNA sequencing market. The article outlines the market's growth trajectory and technological trends, but does not provide specific sentiment or performance data for Oxford Nanopore.

Global DNA Sequencing in Drug Discovery Market Report 2026 | Capitalize on 12.5% CAGR as Illumina, Thermo Fisher, QIAGEN, and Oxford Nanopore Accelerate AI-Driven Precision R&D Dublin, Oct. 26, 2026 (GLOBE NEWSWIRE) -- "Deoxyribonucleic Acid (DNA) Sequencing in Drug Discovery Market Report 2026" has been added to ResearchAndMarkets.com's offering.

DNA Sequencing in Drug Discovery Market to Reach $15.22 Billion by 2030 as Precision Medicine Advances

The global deoxyribonucleic acid (DNA) sequencing in drug discovery market is experiencing rapid growth as pharmaceutical and biotechnology companies expand genomic research and adopt advanced sequencing technologies. The market is projected to increase from $8.46 billion in 2025 to $9.49 billion in 2026, representing a compound annual growth rate (CAGR) of 12.3%.

Growth during the historical period has been supported by rising investment in genomic research, expanding pharmaceutical research and development pipelines, greater availability of high-throughput sequencing platforms, improvements in sequencing speed and accuracy, and increased emphasis on personalized medicine. DNA sequencing is becoming increasingly important throughout drug discovery because it enables researchers to identify genetic variations, biomarkers and therapeutic targets associated with disease progression and treatment response.

The DNA sequencing in drug discovery market is forecast to reach $15.22 billion by 2030, expanding at a CAGR of 12.5%. Key growth factors include the adoption of artificial intelligence-driven genomic analysis, increasing demand for targeted therapeutics, broader pharmacogenomics applications and greater use of sequencing in early-stage drug screening. Collaboration among pharmaceutical companies, biotechnology firms and genomics specialists is also expected to accelerate research and support the development of more precise drug candidates.

Personalized medicine remains a major market driver. Advances in genomics and molecular diagnostics allow researchers and clinicians to identify genetic and molecular differences among patients, improving drug selection and supporting treatments with greater efficacy and fewer adverse effects. DNA sequencing contributes to this process by detecting patient-specific genetic variations and enabling biomarker-driven therapy development.

Regulatory activity demonstrates the expanding role of personalized treatments. According to the Personalized Medicine Coalition, the U.S. Food and Drug Administration approved 16 new personalized treatments for patients with rare diseases in 2023, compared with six in 2022. The 2023 approvals also included seven cancer therapies and three treatments for other diseases and conditions. This increase highlights the growing importance of genomic information in therapeutic research, clinical development and regulatory decision-making.

Technology innovation is reshaping the competitive landscape. Major DNA sequencing in drug discovery trends include increased use of next-generation sequencing for target identification, rising adoption of single-cell sequencing, integration of bioinformatics into research workflows, expansion of precision medicine programs and stronger emphasis on biomarker-based drug development. High-resolution DNA methylation sequencing and multiomic analysis are also helping researchers examine epigenetic and chromatin features more efficiently.

In April 2025, EpiCypher Inc. launched CUTANA mCUT&RUN and Multiomic CUT&RUN, DNA methylation sequencing assays designed to deliver high-resolution profiling while reducing sequencing costs and sample input requirements. The assays allow researchers to analyze DNA methylation and chromatin features simultaneously, generating multiomic insights into gene regulation. These capabilities can improve target identification and validation while supporting faster, more cost-effective drug discovery programs.

Market consolidation and strategic acquisitions are also strengthening sequencing capabilities. In May 2025, Mapmygenome India Pvt. Ltd. acquired Microbiome Insights for an undisclosed amount. The transaction is intended to enhance Mapmygenome's microbiome research and sequencing expertise, broaden its integrated genomics and microbiome services, and support its expansion into North America. Microbiome Insights provides DNA sequencing services for pharmaceutical and biotechnology drug discovery, development and clinical trial programs.

The market includes sequencing instruments, consumables and associated services used across sample preparation, sequencing and genomic analysis workflows. Core technologies include Sanger sequencing and next-generation sequencing, while major applications encompass drug discovery and pharmacogenomics. Pharmaceutical companies and biotechnology firms represent the principal end users. Service categories include whole-genome sequencing, whole-exome sequencing, targeted sequencing, Sanger sequencing and single-cell sequencing.

Tariffs are creating additional cost pressures by increasing the price of imported sequencing instruments, reagents, flow cells and data-processing hardware. Pharmaceutical and biotechnology organizations in North America and Europe face significant exposure because of their reliance on imported high-end sequencing platforms, while Asia-Pacific markets are experiencing pressure across consumables supply chains. Although these conditions can raise research costs and extend project timelines, they are also encouraging domestic manufacturing, regional supplier diversification and increased investment in local genomics infrastructure.

Markets Covered:

1) By Product Type: Instruments; Consumables

2) By Workflow: Sample Preparation; Sequencing

3) By Technology Type: Sanger Sequencing; Next-Generation Sequencing (NGS)

4) By Application: Drug Discovery; Pharmacogenomics

5) By End-User: Pharmaceutical Companies; Biotechnology Firms

Subsegments:

1) By Instruments: Sequencing Systems; Sample Preparation Systems; Detection and Imaging Systems; Automation and Robotics Systems; Data Analysis Hardware

2) By Consumables: Sequencing Reagents; Library Preparation Kits; Sample Collection Kits; Flow Cells; Quality Control Reagents

Time Series: Five years historic and ten years forecast.

Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.

Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.

Key Attributes:

Companies Featured

The companies featured in this Deoxyribonucleic Acid (DNA) Sequencing in Drug Discovery market report include:

For more information about this report visit https://www.researchandmarkets.com/r/badua2

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.